The clinical outcome of HIV infection at a tertiary care center in Riyadh, Saudi Arabia

References

1. ↵
   1. Joint United Nations Programme on HIV/AIDS (UNAIDS)

   (2018) Report on the Global AIDS Epidemic (UNAIDS, Geneva), pp 1–6.
2. ↵
   1. The Joint United Nations Programme on HIV/AIDS

   (2014) Regional Sub-Saharan Africa, 1–7.
3. ↵
   1. Obermeyer CM

   (2006) HIV in the Middle East. BMJ 333:851–854.

   OpenUrlFREE Full Text
4. ↵
   1. Al-Mozaini M,
   2. Alrahbeni T,
   3. Al-Mograbi R,
   4. Alrajhi A

   (2018) Antiretroviral resistance in HIV-1 patients at a tertiary medical institute in Saudi Arabia:a retrospective study and analysis. BMC Infect Dis 18:425.

   OpenUrl
5. ↵
   National Aids Program - KSA (NAPKSA), cited 2020 Available at: https://www.linkedin.com/in/napmoh/?originalSubdomain=sa.
6. ↵
   1. Palella FJ Jr.,
   2. Delaney KM,
   3. Moorman AC,
   4. et al.

   (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338:853–860.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Falster K,
   2. Choi JY,
   3. Donovan B,
   4. Duncombe C,
   5. Mulhall B,
   6. Sowden D,
   7. et al.

   (2009) AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 23:2323–2336.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Morlat P,
   2. Roussillon C,
   3. Henard S,
   4. Salmon D,
   5. Bonnet F,
   6. Cacoub P,
   7. et al.

   (2014) Causes of death among HIV-infected patients in France in 2010 (national survey):trends since 2000. AIDS 28:1181–1191.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Hogg R

   (2008) Antiretroviral therapy cohort collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries:a collaborative analysis of 14 cohort studies. Lancet 372:293–299.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Tsertsvadze T,
    2. Bolokadze N,
    3. Gochitashvili N,
    4. et al.

    (2009) Experience of antiretroviral treatment in Georgia. Cent Eur J Public Health 17:25–30.

    OpenUrlPubMed
11. 1. Schwarcz SK,
    2. Vu A,
    3. Hsu LC,
    4. Hessol NA

    (2014) Changes in causes of death among persons with AIDS:San Francisco, California 1996-2011. AIDS Patient Care STDS 28:517–523.

    OpenUrlCrossRefPubMed
12. 1. Grande E,
    2. Zucchetto A,
    3. Suligoi B,
    4. et al.

    (2017) Multiple cause-of-death data among people with AIDS in Italy:a nationwide cross-sectional study. Popul Health Metr 15:19.

    OpenUrl
13. ↵
    1. Smith CJ,
    2. Ryom L,
    3. Weber R,
    4. et al.

    (2014) Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D):a multicohort collaboration. Lancet (London, England) 384:241–248.

    OpenUrl
14. ↵
    1. Braitstein P,
    2. Brinkhof MW,
    3. Dabis F,
    4. et al.

    (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:comparison between low-income and high-income countries. Lancet 367:817–824.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Günthard HF,
    2. Saag MS,
    3. Benson CA,
    4. del Rio C,
    5. Eron JJ,
    6. Gallant JE,
    7. et al.

    (2016) Antiretroviral drugs for treatment and prevention of HIV infection in adults:2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 316:191–210.

    OpenUrlCrossRefPubMed
16. ↵
    1. Deeks SG,
    2. Lewin SR,
    3. Havlir DV

    (2013) The end of AIDS:HIV infection as a chronic disease. Lancet 382:1525–1533.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Paul S,
    2. Gilbert HM,
    3. Ziecheck W,
    4. Jacobs J,
    5. Sepkowitz KA

    (1999) The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 13:415–418.

    OpenUrlCrossRefPubMedWeb of Science
18. 1. Paul S,
    2. Gilbert HM,
    3. Ziecheck W,
    4. Jacobs J,
    5. Sepkowitz KA

    (1999) The changing pattern of admissions to a London hospital of patients with HIV 1988-1997. Royal Free Centre for HIV Medicine. AIDS 13:1255–1261.

    OpenUrlCrossRefPubMedWeb of Science
19. 1. Gebo KA,
    2. Fleishman JA,
    3. Moore RD

    (2005) Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients. J Acquir Immune Defic Syndr 40:609–616.

    OpenUrlCrossRefPubMedWeb of Science
20. 1. Gutierrez F,
    2. Padilla S,
    3. Masia' M,
    4. et al.

    (2006) Clinical outcome of HIV infected patients with sustained virologic response to antiretroviral therapy:Long- term follow-up of a multicenter cohort. PLoS One 1:1–7.

    OpenUrlCrossRef
21. ↵
    1. Farahani M,
    2. Mulinder H,
    3. Farahani A,
    4. Marlink R

    (2017) Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy:a systematic review and meta-analysis. Int J STD AIDS 28:636–650.

    OpenUrl
22. ↵
    1. Al-Mazrou YY,
    2. Al-Jeffri MH,
    3. Fidail AI,
    4. et al.

    (2005) HIV/AIDS epidemic features and trends in Saudi Arabia. Ann Saudi Med 25:100–104.

    OpenUrlPubMedWeb of Science
23. ↵
    1. Al-Mozaini MA,
    2. Mansour MK,
    3. Al-Hokail AA,
    4. et al.

    (2014) HIV-Care Outcome in Saudi Arabia;a Longitudinal Cohort. J AIDS Clin Res 5:1490–1497.

    OpenUrl
24. ↵
    1. Alrajhi AA,
    2. Halim MA,
    3. Al-Abdely HM

    (2004) Mode of transmission of HIV-1 in Saudi Arabia. AIDS 18:1478–1480.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Adland E,
    2. Klenerman P,
    3. Goulder P,
    4. Matthews PC

    (2015) Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. Front Microbiol 6:1016.

    OpenUrlCrossRef
26. ↵
    1. Grønborg HL,
    2. Jespersen S,
    3. Hønge BL,
    4. Jensen-Fangel S,
    5. Wejse C

    (2017) Review of cytomegalovirus coinfection in HIV-infected individuals in Africa. Rev Med Virol 27:e1907.
27. ↵
    1. Kaplan JE,
    2. Benson C,
    3. Holmes KK,
    4. Brooks JT,
    5. Pau A,
    6. Masur H

    (2009) Centers for Disease Control and Prevention (CDC);National Institutes of Health;HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58(RR-4):1–207.
28. ↵
    1. Bajhmoum W,
    2. Memish Z,
    3. Ali B,
    4. Beeching N

    (2014) Clinical features and epidemiology of HIV and coinfection with TB and/or viral hepatitis in a large clinic in Jeddah,Kingdom of Saudi Arabia. HIV Med 15(S3):17–159.
29. ↵
    1. Low A,
    2. Gavriilidis G,
    3. Larke N,
    4. et al.

    (2016) Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low and middle-income countries:A systematic review and meta-analysis. Clin Infect Dis 62:1595–1603.
30. ↵
    1. Alenazi TH,
    2. Alanazi BS,
    3. Alsaedy A,
    4. et al.

    (2019) Mycobacterium riyadhense as the opportunistic infection that lead to HIV diagnosis:A report of 2 cases and literature review. J Infect Public Health 12:285–288.
31. ↵
    1. Varghese B,
    2. Enani MA,
    3. Althawadi S,
    4. Johani S,
    5. Fernandez GM,
    6. Al-Ghafli H,
    7. et al.

    (2017) Mycobacterium riyadhense in Saudi Arabia. Emerg Infect Dis 23:1732–1734.
32. ↵
    1. Huang L,
    2. Cattamanchi A,
    3. Davis JL,
    4. den Boon S,
    5. Kovacs J,
    6. Meshnick S,
    7. et al.

    (2011) HIV-associated Pneumocystis pneumonia. Proc Am Thorac Soc 8:294–300.
33. ↵
    1. Tasaka S

    (2015) Pneumocystis pneumonia in human immunodeficiency virus-infected adults and adolescents:Current concepts and future directions. Clin Med Insights Circ Respir Pulm Med 9(Suppl 1):19–28.
34. ↵
    1. Roux A,
    2. Canet E,
    3. Valade S,
    4. Gangneux-Robert F,
    5. Hamane S,
    6. Lafabrie A,
    7. et al.

    (2014) Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 20:1490–1497.
35. 1. Guo F,
    2. Chen Y,
    3. Yang SL,
    4. Xia H,
    5. Li XW,
    6. Tong ZH

    (2014) Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients:a retrospective study of two centers in China. PLoS One 9:e101943.
36. ↵
    1. Schmidt JJ,
    2. Lueck C,
    3. Ziesing S,
    4. et al.

    (2018) Clinical ourse, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults:a retrospective analysis over 17 years. Crit Care 22:307.
37. ↵
    1. Alhuraiji A,
    2. Alaraj A,
    3. Alghamdi S,
    4. Alrbiaan A,
    5. Alrajhi AA

    (2014) Viral hepatitis B and C in HIV-infected patients in Saudi Arabia. Ann Saudi Med 34:207–210.
38. ↵
    1. Palella FJ Jr.,
    2. Baker RK,
    3. Moorman AC,
    4. Chmiel JS,
    5. Wood KC,
    6. et al.

    (2006) Mortality in the highly active antiretroviral therapy era:changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43:27–34.
39. ↵
    1. Carbone A,
    2. Cesarman E,
    3. Spina M,
    4. Gloghini A,
    5. Schulz TF

    (2009) HIV-associated lymphomas and gamma-herpesviruses. Blood 113:1213–1224.
40. ↵
    1. Brunnberg U,
    2. Hentrich M,
    3. Hoffmann C,
    4. Wolf T,
    5. Hübel K

    (2017) HIV-Associated Malignant Lymphoma. Oncol Res Treat 40:82–87.
41. ↵
    1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

    (1998) Afr J Med Pract 5:79–104.
42. ↵
    1. Sluis-Cremer N

    1. Bila DCA,
    2. Boullosa LT,
    3. Vubil AS,
    4. et al.

    (2015) Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique. in PLoS One, ed Sluis-Cremer N 10:e0130580.
43. 1. Nii-Trebi NI,
    2. Ibe S,
    3. Barnor JS,
    4. Ishikawa K,
    5. Brandful JA,
    6. Ofori SB,
    7. et al.

    (2013) HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana. PLoS One 8:e71972.
44. ↵
    1. Marconi VC,
    2. Sunpath H,
    3. Lu Z,
    4. et al.

    (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46:1589–1597.